A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Nebulized Ampion In Adults With Respiratory Distress Secondary to COVID-19 Infection
Latest Information Update: 22 Mar 2022
At a glance
- Drugs DMI 9523 (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Adverse reactions
- Sponsors Ampio Pharmaceuticals
Most Recent Events
- 27 Jul 2021 According to an Ampio Pharmaceuticals media release, data from this trial will be presented at 63rd annual Thomas L. Petty Aspen Lung Conference
- 27 Jul 2021 Results published in an Ampio Pharmaceuticals Media Release
- 21 May 2021 Status changed from active, no longer recruiting to completed, according to an Ampio Pharmaceuticals media release.